Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T66237 | Target Info | |||
Target Name | Vasopressin V2 receptor (V2R) | ||||
Synonyms |
Renal-type arginine vasopressin receptor; DIR3; DIR; Antidiuretic hormone receptor; AVPR V2; ADHR
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | AVPR2 | ||||
Biochemical Class | GPCR rhodopsin | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | Vasopressin V1b receptor (V1BR) | Successful Target | ||||
UniProt ID | V1BR_HUMAN | |||||
Gene Name | AVPR1B | |||||
Synonyms |
Vasopressin V3 receptor; Vasopressin V(1b) Receptor; VPR3; V1bR; Antidiuretic hormone receptor 1b; AVPR3; AVPR V3; AVPR V1b
Click to Show/Hide
|
|||||
Representative Drug(s) | Vasopressin | Drug Info | EC50 = 0.0035 nM | Click to Show More | [1] | |
2 | Oxytocin | Drug Info | EC50 = 0.2 nM | [2] | ||
3 | SSR149415 | Drug Info | Ki = 0.6 nM | [5] | ||
4 | Desmopressin | Drug Info | Ki = 5.8 nM | [7] | ||
5 | ATOSIBAN | Drug Info | Ki = 44 nM | [3] | ||
Co-Target Name | Vasopressin V1a receptor (V1AR) | Successful Target | ||||
UniProt ID | V1AR_HUMAN | |||||
Gene Name | AVPR1A | |||||
Synonyms |
Vascular/hepatic-type arginine vasopressin receptor; V1aR; V1a vasopressin receptor; Antidiuretic hormone receptor 1a; AVPR1; AVPR V1a
Click to Show/Hide
|
|||||
Representative Drug(s) | Vasopressin | Drug Info | EC50 = 0.004 nM | Click to Show More | [1] | |
2 | ATOSIBAN | Drug Info | Ki = 0.15 nM | [3] | ||
3 | Oxytocin | Drug Info | EC50 = 0.18 nM | [2] | ||
4 | Conivaptan | Drug Info | Ki = 0.43 nM | [4] | ||
5 | SSR149415 | Drug Info | Ki = 22 nM | [5] | ||
6 | Lixivaptan | Drug Info | Ki = 44 nM | [8] | ||
7 | Desmopressin | Drug Info | Ki = 62.4 nM | [7] | ||
8 | Mozavaptan | Drug Info | Ki = 195 nM | [10] | ||
9 | Satavaptan | Drug Info | Ki = 304 nM | [11] | ||
Co-Target Name | Oxytocin receptor (OTR) | Successful Target | ||||
UniProt ID | OXYR_HUMAN | |||||
Gene Name | OXTR | |||||
Synonyms |
OT-R
Click to Show/Hide
|
|||||
Representative Drug(s) | Oxytocin | Drug Info | EC50 = 0.0046 nM | Click to Show More | [2] | |
2 | Vasopressin | Drug Info | EC50 = 0.1 nM | [1] | ||
3 | SSR149415 | Drug Info | Ki = 1.514 nM | [6] | ||
4 | ATOSIBAN | Drug Info | Ki = 11 nM | [3] | ||
5 | Desmopressin | Drug Info | EC50 = 72 nM | [9] | ||
6 | Lixivaptan | Drug Info | IC50 = 519 nM | [12] | ||
7 | Mozavaptan | Drug Info | Ki = 660 nM | [10] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. J Med Chem. 2019 Apr 11;62(7):3297-3310. | ||||
REF 2 | Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors. Bioorg Med Chem. 2019 Aug 1;27(15):3358-3363. | ||||
REF 3 | The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. | ||||
REF 4 | Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3742-5. | ||||
REF 5 | Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. | ||||
REF 6 | The characterization of a novel V1b antagonist lead series. Bioorg Med Chem Lett. 2011 Jan 1;21(1):92-6. | ||||
REF 7 | Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. | ||||
REF 8 | Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2747-52. | ||||
REF 9 | New, potent, and selective peptidic oxytocin receptor agonists. J Med Chem. 2014 Jun 26;57(12):5306-17. | ||||
REF 10 | Selective fluorescent nonpeptidic antagonists for vasopressin V? GPCR: application to ligand screening and oligomerization assays. J Med Chem. 2012 Oct 25;55(20):8588-602. | ||||
REF 11 | Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling. J Med Chem. 2018 Nov 21;61(22):10173-84. | ||||
REF 12 | Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5796-800. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.